MannKind Corporation (Nasdaq: MNKD) announced positive topline results from INFLO-1, its Phase 1b clinical study evaluating an inhaled dry powder ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE